SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Reaffirm 10.1% Passive Stake in Beam Therapeutics Inc.

Sentiment:

Beneficial Ownership Report 2 April 2025 3:02 PM

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reaffirming their beneficial ownership of 10.1% of Beam Therapeutics Inc.'s common stock as of March 31, 2025.

Summary

FMR LLC and Abigail P. Johnson collectively beneficially own 10,042,092.33 shares of Beam Therapeutics Inc. common stock.
This ownership represents 10.1% of the total outstanding common stock of Beam Therapeutics Inc.
FMR LLC holds sole voting power over 10,032,758.00 shares and sole dispositive power over 10,042,092.33 shares.
Abigail P. Johnson, as a Director, Chairman, and CEO of FMR LLC, is deemed to beneficially own the same aggregate amount of shares due to her control over FMR LLC.
The filing is an Amendment No. 8 to a Schedule 13G, indicating a continued reporting obligation for a significant passive stake.
The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing itself is neutral as a regulatory disclosure. However, the continued significant passive ownership by a major institutional investor like FMR LLC can be interpreted as a positive signal of long-term confidence in the issuer, Beam Therapeutics Inc.

Positives

Continued significant institutional investment by FMR LLC, a major asset manager, indicates sustained confidence in Beam Therapeutics Inc.
The passive nature of the investment, as stated in the certification, suggests no immediate intent to influence or change control, providing stability for the issuer.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Beam Therapeutics Inc.'s future operations or financial performance. It primarily reflects the continued passive investment stance of FMR LLC and Abigail P. Johnson.

Management Comments

The filing includes a certification from FMR LLC and Abigail P. Johnson stating that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Beam Therapeutics Inc., nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a routine disclosure for significant passive investors in publicly traded companies. For Beam Therapeutics Inc., a biotechnology company, a stable institutional ownership stake from a major asset manager like FMR LLC can be viewed positively, signaling long-term interest in the sector and the company's potential, without indicating any immediate strategic shifts or activist intentions.

Comparison to Industry Standards

This document is a standard regulatory filing (Schedule 13G) for reporting beneficial ownership exceeding 5%.
The 10.1% stake held by FMR LLC and Abigail P. Johnson is a substantial passive investment, common for large institutional asset managers like Fidelity (FMR LLC's parent).
While specific comparable companies or projects are not mentioned in the filing, such ownership levels are typical for major investment firms holding positions across various industries, including the biotechnology sector, where long-term growth potential often attracts significant institutional capital.

Stakeholder Impact

Shareholders: The continued significant passive stake by a major institutional investor may provide a sense of stability and long-term confidence.
Management: The passive nature of the investment indicates no immediate pressure for strategic changes from this particular shareholder.

Next Steps

The document does not specify any future actions or milestones for Beam Therapeutics Inc. It is a backward-looking report of ownership as of March 31, 2025.
FMR LLC and Abigail P. Johnson will continue to file amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., by more than 1%) or if their investment intent changes from passive to active.

Key Dates

Date	Description
2023-01-03	Effective date of Power of Attorney for Stephanie J. Brown on behalf of FMR LLC.
2023-01-10	Date of Schedule 13G filing by FMR LLC where the Power of Attorney (accession number -23-000003) was incorporated by reference.
2023-01-26	Effective date of Power of Attorney for Stephanie J. Brown on behalf of Abigail P. Johnson.
2023-01-31	Date of Schedule 13G filing by FMR LLC where the Power of Attorney (accession number -23-000038) for Abigail P. Johnson was incorporated by reference.
2025-03-31	Date of event which requires filing of this statement (reporting date for beneficial ownership).
2025-04-01	Signature date of the Schedule 13G filing.

Keywords

Beam Therapeutics Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Gene Editing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.